Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NICE Gives Thumbs Down to Simponi--For Now

This article was originally published in The Pink Sheet Daily

Executive Summary

The controversial health technology assessment agency is unconvinced of the drug's cost benefit in a crowded market, which is already well served, and concerned about its long-term safety profile.

You may also be interested in...



With Discount In Place, NICE Gives Nod To Amgen's Nplate For Bleeding Disorder

Discount scheme helps draw long-running NICE appraisal of Amgen's Nplate to a positive conclusion.

With Discount In Place, NICE Gives Nod To Amgen's Nplate For Bleeding Disorder

Discount scheme helps draw long-running NICE appraisal of Amgen's Nplate to a positive conclusion.

Evidence Insufficient To Compare Psoriatic Arthritis Drugs – AHRQ

A comparative effectiveness study on drug therapies used to treat psoriatic arthritis in adults determined that the evidence is insufficient to draw any conclusions.

Related Content

Topics

UsernamePublicRestriction

Register

PS071405

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel